SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid mixed signals, with community frustration mounting over its stock performance despite positive developments. While initial discussion revolved around rumors of Nvidia abandoning Intel's 18A process, the recent clearance of Nvidia's $5 billion investment in Intel and the company's partnership in the US Department of Energy's "Genesis Mission" for AI are fueling optimism among long-term bulls regarding its advanced foundry initiatives and US government support.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending with high anticipation for an imminent FDA approval decision on its first-in-class drug, Narsoplimab, further amplified by a recent trading halt indicating news is pending. The community is buzzing with optimism for a positive outcome, expecting significant market movement and a potential short squeeze, especially given the company's strengthened financial standing from a major partnership deal.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a key milestone toward direct-to-device cellular broadband for standard smartphones. The community is buzzing with excitement over this validation of their next-generation technology, anticipating long-term bullish momentum as the company progresses toward commercial scalability. While many celebrate, some investors are also discussing potential short-term profit-taking given the recent run-up and holiday trading conditions.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is trending as the community anticipates upcoming showcases at CES 2026 and Qubits26, expected to highlight its commercial quantum computing applications and progress. While many express bullish sentiment on its long-term potential in a critical future industry, others debate its high volatility, current valuation relative to revenue, and executive share sales.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is a major talking point following its announced inclusion in the S&P MidCap 400. This news is generating significant community excitement, anticipating increased institutional demand, enhanced visibility, and a potential short squeeze. Investors are highlighting its strong financial position and its critical role in the rapidly evolving agentic AI and automation sector as key drivers for future growth.

Starfighters Space Inc

Starfighters Space Inc. ($FJET), a recent IPO in the aerospace sector, is experiencing extreme volatility, rocketing higher after its debut and subsequently plummeting. The community is sharply divided, with bulls anticipating a massive short squeeze and further "Mach 2" ascent due to its low float, while bears label it an overvalued "pump and dump" with questionable fundamentals and high dilution risk. This has created a highly speculative trading environment, with many discussing its potential as a meme stock versus a rapid decline.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending following its acquisition by Sanofi, prompting widespread congratulatory messages among shareholders and discussions around the valuation of the deal. The acquisition, which enhances Sanofi's vaccine portfolio with Dynavax's Hepatitis B vaccine and shingles treatment, also fuels conversations regarding the implications for Vaxart due to their oral COVID-19 vaccine licensing agreement. This development provides a significant exit for long-term investors amid prior frustrations concerning management and shareholder value.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending due to multiple strategic partnerships focused on deploying its advanced thin-film solar technology across aerospace, defense, and terrestrial applications. The community is actively discussing the stock's significant price and volume surges, viewing it as a high-potential speculative play driven by the burgeoning space economy and demand for resilient power in extreme environments.

Maase, Inc. engages in the provision of intelligent technology-driven family and enterprise services. It operates through the following business segments: Insurance Agency and Wealth Management. The Insurance Agency segment involves in providing agency services for distributing life and non-life insurance products on behalf of insurance companies. The Wealth Management segment offers financial advisory, investment planning, and asset management services for individuals, families, and corporate clients, utilizing data-driven insights and digital platforms to optimize financial outcomes. The company was founded by Hai Feng Yu on August 6, 2018, and is headquartered in Guangzhou, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is trending following its strategic acquisitions, notably a pivot into the healthcare sector with biotech and wild ginseng resources, alongside earlier moves in EV charging and smart tech. This aggressive diversification is fueling a polarized debate, with proponents highlighting the low float and asset-backed growth potential, while skeptics caution about its history as a volatile Chinese microcap. The stock is also gaining attention amid a broader market rotation where capital is shifting from crowded mega-cap tech into under-the-radar small-cap plays.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis (AVNT CRYPTO) is generating significant discussion, largely fueled by its recent listing on Robinhood and its strong association with Coinbase's #base app, positioning it as a key player in the perp DEX space. The community is sharply divided, with many anticipating massive upside potential and comparing it favorably to rivals like Aster, while others express deep frustration over price performance, alleged dilution, and persistent short pressure. This polarization creates an intense debate among investors over its immediate future and long-term viability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

ALXN
Alexion Pharmaceuticals, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest ALXN News

ALXNAlexion Pharmaceuticals, Inc.